Электронный архив

Просмотр по автору "Mingaleeva R."

Просмотр по автору "Mingaleeva R."

Отсортировать по:Сортировать:Результаты поиска на странице:

  • Application of cell and tissue culture systems for anticancer drug screening 
    Blatt N.; Mingaleeva R.; Khaiboullina S.; Lombardi V.; Rizvanov A. (2013)
    A primary reason why potential anticancer drugs fail in clinical trials is the limitations of existing in vitro screening systems. The purpose of in vitro testing is to aid in the selection of efficacious compounds from a ...
  • Application of cell and tissue cultures for potential anti-cancer/oncology drugs screening in vitro 
    Mingaleeva R.; Solovieva V.; Blatt N.; Rizvanov A. (2013)
    One of the reasons for the failure of potential anticancer drugs in clinical trials is the imperfection of existing preclinical screening systems. Perhaps the most important step is in vitro testing during which several ...
  • Cancer stem cells: 20 years behind 
    Mingaleeva R.; Miftakhova R.; Rizvanov A. (2015)
    The biology of cancer stem cells (CSC) has been investigated and debated for past 20 years. Owning to their exceptional plasticity and the complexity of controlled processes CSC inspire the development of new research ...
  • In vivo screening models of anticancer drugs 
    Blatt N.; Mingaleeva R.; Khaiboullina S.; Kotlyar A.; Lombardi V.; Rizvanov A. (2013)
    Animal models have been indispensable when conducting research to further the understanding of cancer biology and when developing anticancer drugs. This article presents an overview of the most commonly utilized animal ...
  • Novel Isatin-based activator of p53 transcriptional functions in tumor cells 
    Mirgayazova R.; Khadiullina R.; Mingaleeva R.; Chasov V.; Gomzikova M.; Garanina E.; Rizvanov A.; Bulatov E. (2019)
    © 2019 Shiraz University. Bioinorganic medicinal chemistry remains a hot field for research aimed at developing novel anti-cancer treatments. Discovery of metal complexes as potent antitumor chemotherapeutics such as ...
  • Therapeutic editing of the TP53 gene: Is crispr/CAS9 an option? 
    Mirgayazova R.; Khadiullina R.; Chasov V.; Mingaleeva R.; Miftakhova R.; Rizvanov A.; Bulatov E. (2020)
    © 2020 by the authors. Licensee MDPI, Basel, Switzerland. The TP53 gene encodes the transcription factor and oncosuppressor p53 protein that regulates a multitude of intracellular metabolic pathways involved in DNA damage ...

Поиск в электронном архиве

Просмотр

Моя учетная запись